| 2025-01-08 | -1.64 % |
|
| 2025-01-07 | -0.66 % |
|
| 2025-01-06 | -0.2 % |
|
| 2025-01-03 | -0.51 % |
|
| 2025-01-02 | -0.53 % |
|
| 2024-12-31 | +0.39 % |
- Gilead Sciences (GILD) stock rose by 0.39% due to a combination of positive market sentiment and potential increased demand for its pharmaceutical products, although specific reasons for this rise were not detailed in the provided article.
- The article discusses Representative Marjorie Taylor Greene's recent stock purchases, including Gilead Sciences, which rose by 0.39% last night, although it does not provide specific reasons for this increase. The rise in Gilead Sciences (GILD) stock may be attributed to overall market conditions, investor sentiment, or specific developments in the company that were not detailed in the article.
- Gilead Sciences (GILD) stock rose 0.39% likely due to positive market sentiment following recent trading activity and analysis trends, though the article primarily discusses Representative Marjorie Taylor Greene's purchase of Adobe shares rather than specific factors affecting Gilead's stock.
- The article discusses a recent increase of 0.39% in Gilead Sciences (GILD) stock, which may be influenced by various factors, including overall market trends, investor sentiment, or specific actions taken by notable investors like Representative Marjorie Taylor Greene purchasing shares, although these details about Gilead are not explicitly mentioned in the provided text.
- The article discusses the recent stock activity of Norfolk Southern Co. and mentions that Gilead Sciences (GILD) stock increased by 0.39%. Gilead Sciences stock's increase could be attributed to overall positive market sentiment, potential favorable developments in their drug portfolio, or investor activity, but specific reasons related to GILD were not detailed in the article provided.
- Gilead Sciences (GILD) stock rose by 0.39% likely due to positive investor sentiment following recent disclosures of stock purchases by Representative Marjorie Taylor Greene and a strong quarterly earnings report that exceeded analysts' expectations.
|
| 2024-12-19 | +0.44 % |
|
| 2024-12-18 | -2.27 % |
|
| 2024-12-17 | +0.81 % |
|
| 2024-12-16 | +0.21 % |
|
| 2024-12-12 | |
|
| 2024-12-02 | +1.56 % |
|
| 2024-11-26 | +0.95 % |
|
| 2024-11-25 | +0.33 % |
|
| 2024-11-21 | +1.27 % |
|
| 2024-11-20 | +1 % |
|
| 2024-11-07 | +6.77 % |
|
| 2024-11-06 | +1.63 % |
|
| 2024-11-05 | +0.42 % |
|
| 2024-11-04 | +0.37 % |
|
| 2024-11-01 | +0.78 % |
|
| 2024-10-31 | +0.6 % |
|
| 2024-10-30 | +0.24 % |
|
| 2024-10-28 | -0.27 % |
|
| 2024-10-25 | +0.25 % |
|
| 2024-10-24 | +1.78 % |
|
| 2024-10-23 | -1.05 % |
|
| 2024-10-22 | +2.17 % |
|
| 2024-10-21 | -0.5 % |
|
| 2024-10-18 | -0.73 % |
|
| 2024-10-17 | +0.7 % |
|
| 2024-10-16 | +1.08 % |
|
| 2024-10-14 | +0.12 % |
|
| 2024-10-11 | +0.33 % |
|
| 2024-10-09 | +1.09 % |
- Gilead Sciences (GILD) stock rose 1.09% following news of institutional investments, with several funds acquiring significant stakes in the biopharmaceutical company, reflecting investor confidence and positive earnings performance.
- Gilead Sciences (GILD) stock rose by 1.09% last night, likely due to positive market sentiment around biopharmaceutical advancements and ongoing commercial efforts, suggesting investor confidence in the company's future growth prospects.
- Gilead Sciences (GILD) stock rose by 1.09% due to significant increases in institutional ownership and positive analyst ratings, indicating strong investor confidence in the company's performance and prospects.
- Gilead Sciences (GILD) stock rose 1.09% after JPMorgan Chase & Co. raised its price target from $95.00 to $100.00, maintaining an overweight rating on the stock, which likely contributed to increased investor confidence.
- Gilead Sciences (NASDAQ:GILD) stock rose 1.09% following an increase in its price target by JPMorgan Chase & Co. from $95 to $100, which reflects positive sentiment about the company's growth potential and earnings performance.
- Gilead Sciences (GILD) stock increased by 1.09% following the company's donation of approximately 5,000 doses of the antiviral Remdesivir to Rwanda in response to an outbreak of the Marburg virus, showcasing its proactive involvement in global health crises which positively impacts investor confidence.
- Gilead Sciences (GILD) stock rose by 1.09% attributed to positive developments related to its collaboration with Nurix Therapeutics, particularly the upcoming presentations of preclinical data for their IRAK4 degrader GS-6791, which could enhance its therapeutic portfolio in autoimmune diseases and align with market interests in innovative biopharmaceuticals.
|
| 2024-10-07 | -0.19 % |
|
| 2024-10-04 | +0.5 % |
|
| 2024-10-03 | -0.67 % |
|
| 2024-10-02 | +0.95 % |
|
| 2024-10-01 | +0.12 % |
|
| 2024-09-26 | +1.01 % |
|
| 2024-09-24 | -0.24 % |
|
| 2024-09-13 | -0.42 % |
|
| 2024-09-12 | +2.74 % |
|
| 2024-09-10 | +2.87 % |
|
| 2024-09-06 | -0.06 % |
|
| 2024-09-05 | -0.45 % |
|
| 2024-08-15 | +0.27 % |
|
| 2024-08-14 | +0.22 % |
|
| 2024-08-09 | -2.55 % |
|
| 2024-08-08 | +2.15 % |
|
| 2024-08-07 | -0.26 % |
|
| 2024-08-06 | -0.86 % |
|
| 2024-08-05 | -2.53 % |
|
| 2024-07-31 | -2.55 % |
|
| 2024-07-25 | +4.1 % |
|
| 2024-07-23 | -1.71 % |
|
| 2024-07-22 | -0.21 % |
|
| 2024-07-18 | +0.29 % |
|
| 2024-07-17 | +2.32 % |
- Summary: Gilead Sciences' stock (GILD) increased by 2.32%, with recent developments including the departure announcement of its Chief Medical Officer, Dr. Merdad Parsey, alongside positive ratings from various financial firms based on promising data from clinical studies and drug pipeline advancements.
Reason for Stock Increase: The stock of Gilead Sciences (GILD) went up due to positive developments such as upgrades by financial firms based on promising data from clinical studies, drug pipeline advancements, and the company's strong outlook in the biopharmaceutical sector.
- The article discusses a comparison between Galapagos (NASDAQ: GLPG) and Acerus Pharmaceuticals (OTCMKTS: ASPCF) as small-cap medical companies, with Galapagos being favored due to a higher consensus target price indicating a potential upside of 30.83%, stronger institutional ownership, and better financial performance metrics compared to Acerus Pharmaceuticals. The increase in Gilead Sciences (GILD) stock by 2.32% is likely due to positive news, market sentiment, or general market conditions.
|
| 2024-07-11 | +1.77 % |
|
